Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study

Pemvidutide showed a “highly statistically significant” treatment effect in patients with alcohol use disorder. Altimmune is going up against Eli Lilly and newcomer Baseline Therapeutics in this space.